Relmada Therapeutics (STU:4E2) Total Stockholders Equity : €66.28 Mil (As of Mar. 2024)

View and export this data going back to 2020. Start your Free Trial

What is Relmada Therapeutics Total Stockholders Equity?

Relmada Therapeutics's Total Stockholders Equity for the quarter that ended in Mar. 2024 was €66.28 Mil. It refers to the net assets owned by shareholders. It does not include minority interest.

Total Stockholders Equity is used to calculate Book Value per Share. Relmada Therapeutics's Book Value per Share for the quarter that ended in Mar. 2024 was €2.20. The ratio of a company's debt over equity can be used to measure how leveraged this company is. Relmada Therapeutics's Debt-to-Equity for the quarter that ended in Mar. 2024 was 0.00.

Relmada Therapeutics Total Stockholders Equity Historical Data

The historical data trend for Relmada Therapeutics's Total Stockholders Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Relmada Therapeutics Total Stockholders Equity Chart

Relmada Therapeutics Annual Data

Trend

Aug13

Jun15

Jun16

Jun17

Jun18

Jun19

Dec20

Dec21

Dec22

Dec23

Total Stockholders Equity

Get a 7-Day Free Trial

6.74

86.79

184.32

132.57

78.27

Relmada Therapeutics Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Total Stockholders Equity	Get a 7-Day Free Trial															117.19	102.76	94.38	78.27	66.28

Relmada Therapeutics (STU:4E2) Total Stockholders Equity Explanation

1. Total Stockholders Equity is used to calculate Book Value per Share.

Relmada Therapeutics's Book Value per Share for the quarter that ended in Mar. 2024 is

Book Value per Share	=	(Total Stockholders Equity	-	Preferred Stock)	/	Shares Outstanding (EOP)
	=	(66.282	-	0)	/	30.1742
	=	2.20

2. The ratio of a company's debt over equity can be used to measure how leveraged this company is.

Relmada Therapeutics's Debt-to-Equity for the quarter that ended in Mar. 2024 is

Debt-to-Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(0	+	0)	/	66.282
	=	0.00

Relmada Therapeutics Total Stockholders Equity Related Terms

Thank you for viewing the detailed overview of Relmada Therapeutics's Total Stockholders Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Relmada Therapeutics (STU:4E2) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Relmada Therapeutics Inc (STU:4E2) » Definitions » Total Stockholders Equity

Comparable Companies

Traded in Other Exchanges

RLMD:USA

Address

2222 Ponce de Leon Boulevard, Floor 3, Coral Gables, FL, USA, 33134

Website

https://www.relmada.com

Relmada Therapeutics Inc is a clinical-stage biotechnology company. It is engaged in developing chemical entities with novel versions of drug products that address areas of high unmet medical need in the treatment of central nervous system diseases. The company is focused on the development of esmethadone (d-methadone, dextromethadone, REL-1017), an N-methyl-D-aspartate (NMDA) receptor antagonist. Its lead product candidate, esmethadone, is an oral agent for the treatment of depression and other potential indications.

Relmada Therapeutics (STU:4E2) Headlines

No Headlines